Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Hikma Pharmaceuticals PLC (LON:HIK) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 1,455.78 and traded as high as GBX 1,480.36. Hikma Pharmaceuticals shares last traded at GBX 1,471, with a volume of 419,157 shares traded.

Hikma Pharmaceuticals News Roundup

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: The U.S. Supreme Court sided with Hikma in the Vascepa patent case, a major legal win that could support Hikma’s generic-drug business and reduce litigation risk. US Supreme Court backs Hikma in Vascepa patent dispute
• Positive Sentiment: Multiple reports say the Court unanimously ruled in Hikma’s favor, reinforcing the broader “skinny label” generic drug strategy and potentially improving sentiment toward Hikma’s U.S. generics portfolio. U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
• Positive Sentiment: Industry coverage highlights that generic drugmakers gained a key victory in the skinny-label patent case, which may strengthen investor confidence in Hikma’s legal position and future generic launches. Generic drugmakers gain key victory in ‘skinny label’ patent case
• Neutral Sentiment: Broader articles on the Supreme Court’s ruling frame it as an important legal precedent for generic-drug patents, but they do not add company-specific catalysts beyond the Hikma decision. Patent, Copyright Holders Coming Up Short at Supreme Court

Analyst Ratings Changes

Several equities research analysts recently weighed in on HIK shares. Jefferies Financial Group increased their price objective on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Berenberg Bank reiterated a “buy” rating and set a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of GBX 2,128.

Hikma Pharmaceuticals Stock Up 0.8%

The firm’s 50 day simple moving average is GBX 1,384.02 and its 200 day simple moving average is GBX 1,455.78. The company has a market cap of £3.13 billion, a price-to-earnings ratio of 8.13, a price-to-earnings-growth ratio of 2.38 and a beta of 0.64. The company has a quick ratio of 1.27, a current ratio of 1.82 and a debt-to-equity ratio of 63.59.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.